On November 11, 2013 ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics, reported that Novartis has licensed the exclusive right to use the Company’s antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an undisclosed target (Press release, Novartis, NOV 11, 2013, View Source [SID:1234503696]). This is the third license to be taken by Novartis — and the fifth to be taken by a major healthcare company — this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In the past year, Novartis, Eli Lilly and Amgen have each licensed exclusive rights to use our industry-leading ADC technology for one or more targets," commented Daniel Junius, President and CEO. "There are now numerous highly promising product candidates in the clinic through our own programs and through our partnerships, with many earlier-stage compounds advancing behind these."

The terms of this third Novartis license are consistent with the license announced last month.